The drugmaker attributes modest revenue growth to new product launches and a 3% list price increase for BAQSIMI.
Amphastar Pharmaceuticals expects BAQSIMI revenue to remain flat or rise by low single digits in Q1 2026. The company cited recent product launches and a 3% list price increase as key drivers behind the growth outlook.
Management described the quarter as a “return to growth,” though competitive pressures and pricing challenges persist. The forecast follows a period of stagnation in BAQSIMI sales, with prior quarters showing minimal revenue expansion.
No immediate market reaction was disclosed in the earnings call summary.